Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2020 | Story Rulanzen Martin | Photo Charl Devenish
Dr Stephanie Cawood has great admiration for two women – her mother and Wagani Maathai. Both strong women from Africa.

Dr Stephanie Cawood from the Centre for Gender and Africa Studies is passionate about the African continent, its people, and especially the women of Africa. As an African studies researcher, Dr Cawood admires a pioneer of feminism in Africa, the late Wangari Maathai, the first African woman to receive a Nobel Prize. 

Dr Cawood is trained in communication science and media studies; her field of specialisation is oral communication, particularly rhetoric and oral tradition.  She obtained her PhD in 2011 with the thesis titled, The Rhetorical Imprint of Nelson Mandela as Reflected in Public Speeches, 1950-2004. 

Some of her most recent research projects include ‘Memorialising Struggle Dynamics of Memory, Space and Power in Post-Liberation Africa’, funded by the British Academy under the Newton Advanced Fellowship.

In the Q&A below, Dr Cawood shares some of her inner thoughts. 


Please tell us about yourself: Who are you and what do you do?
I am a Senior Lecturer in and Director of the Centre for Gender and Africa Studies at the UFS. This means that I am engaged in teaching, research, and strategic leadership.

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?
There are many women I admire. I find great inspiration in ordinary people doing extraordinary things. On a personal level, my mum has always inspired me. For a long time, she was involved in labour relations; I have always admired her ability to keep calm and to think rationally and strategically in the face of adversity. From a feminist standpoint, I greatly admire the late Nobel peace prize winner, Wangari Maathai. She was the founder of the Green Belt Movement in Kenya and the first African woman to win the Nobel peace prize for her environmental, political, and feminist activism. In 1971, she obtained her PhD in Science from the University College of Nairobi when it was not common for women to do so. Her life is testament to the fact that it only takes one person to start a movement and to make a change. 

What are some of the challenges you’ve faced in your life that have made you a better woman?
I believe you should look to the future rather than get stuck in the past. I try to constantly learn from my experiences so that I don’t repeat mistakes and can learn to anticipate future challenges and circumvent them. 

What advice would you give to the 15-year-old you?
Enjoy life and don’t be afraid of thinking independently. It’s a good thing. 

What would you say makes you a champion woman [of the UFS]?
I’m not afraid of trying new things and thinking and doing things in unique and unconventional ways. I am a firm believer in treating people with humanity and respect and I try to live by this creed, although I’m not always successful. The key is in trying to do better every day.  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept